Ginkgo Bioworks Holdings Inc [NYSE: DNA] gained 2.54% or 0.03 points to close at $1.21 with a heavy trading volume of 20430924 shares. The company report on January 15, 2024 at 7:00 AM that Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world.
The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric’s global network .
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally.
The daily chart for DNA points out that the company has recorded -46.93% loss over the past six months.
If we look at the average trading volume of 21.06M shares, DNA reached to a volume of 20430924 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Ginkgo Bioworks Holdings Inc [DNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DNA shares is $3.05 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DNA stock is a recommendation set at 3.14. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Ginkgo Bioworks Holdings Inc shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on November 14, 2023.
The Average True Range (ATR) for Ginkgo Bioworks Holdings Inc is set at 0.11, with the Price to Sales ratio for DNA stock in the period of the last 12 months amounting to 7.68. The Price to Book ratio for the last quarter was 1.79, with the Price to Cash per share for the same quarter was set at 0.53.
Trading performance analysis for DNA stock
Ginkgo Bioworks Holdings Inc [DNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.70. With this latest performance, DNA shares dropped by -23.42% in over the last four-week period, additionally sinking by -46.93% over the last 6 months – not to mention a drop of -33.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DNA stock in for the last two-week period is set at 34.00, with the RSI for the last a single of trading hit 28.31, and the three-weeks RSI is set at 38.20 for Ginkgo Bioworks Holdings Inc [DNA]. The present Moving Average for the last 50 days of trading for this stock 1.4678, while it was recorded at 1.2120 for the last single week of trading, and 1.6551 for the last 200 days.
Ginkgo Bioworks Holdings Inc [DNA]: A deeper dive into fundamental analysis
Ginkgo Bioworks Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.78 and a Current Ratio set at 6.78.
Ginkgo Bioworks Holdings Inc [DNA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Ginkgo Bioworks Holdings Inc posted -0.09/share EPS, while the average EPS was predicted by analysts to be reported at -0.21/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 57.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Ginkgo Bioworks Holdings Inc go to 31.70%.
An analysis of Institutional ownership at Ginkgo Bioworks Holdings Inc [DNA]
The top three institutional holders of DNA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in DNA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in DNA stock with ownership which is approximately 5.8325%.
